Compare GDYN & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDYN | KURA |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 727.6M | 1.0B |
| IPO Year | N/A | N/A |
| Metric | GDYN | KURA |
|---|---|---|
| Price | $9.28 | $11.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $11.25 | ★ $25.00 |
| AVG Volume (30 Days) | 963.0K | ★ 1.7M |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 457.52 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $405,955,000.00 | $104,029,000.00 |
| Revenue This Year | $19.77 | $138.16 |
| Revenue Next Year | $10.24 | $67.37 |
| P/E Ratio | $56.81 | ★ N/A |
| Revenue Growth | ★ 23.63 | N/A |
| 52 Week Low | $7.37 | $5.41 |
| 52 Week High | $25.50 | $12.49 |
| Indicator | GDYN | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 51.40 | 52.89 |
| Support Level | $9.32 | $9.68 |
| Resistance Level | $9.95 | $11.28 |
| Average True Range (ATR) | 0.38 | 0.56 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 17.54 | 52.47 |
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.